Floatz Rating
C39/100
Confidence
Indicative
Sponsor
Memorial Sloan Kettering Cancer Center
Modality
Small molecule
Development Phase
Early Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
24Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06145399CT.gov A Study of 1 8F-FDHT PET/MRIScans in Women With Breast Cancer | — | Withdrawn | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Female Breast Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Dihydrotestosterone (this asset) | Memorial Sloan Kettering Cancer Center | Early P1 | C · 39 |
| Anastrozole | Ahon Pharmaceutical Co., Ltd. | P4 | BBB |
| Propofol | Tata Memorial Centre | P4 | BB |
| Sevoflurane | Tata Memorial Centre | P4 | BB |
| Goserelin | Ahon Pharmaceutical Co., Ltd. | P3 | BB |
| Toremifene | Peking Union Medical College Hospital | P4 | BB |
| Fulvestrant | Ahon Pharmaceutical Co., Ltd. | P3 | BB |
| Trastuzumab Deruxtecan | Sun Yat-sen University | P3 | B |
| Melatonin | Virginia Commonwealth University | P3 | B |
+13 more in the Female Breast Carcinoma cohort
Other indications for Dihydrotestosterone
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Carcinoma | — | Early P1 | C · 38 |
| Breast Cancer | — | Early P1 | C · 33 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Dihydrotestosterone in Female Breast Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/dihydrotestosterone-female-breast-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →